Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for military-related posttraumatic stress disorder. For more information, please visit www.thehonorstudy.com or www.clinicaltrials.gov (NCT03062540).

News / Press Releases

: Press Releases

Press Releases

Tonix Pharmaceuticals Reports Outcomes from U.S. FDA Breakthrough Therapy CMC Guidance Meeting of Tonmya® (Cyclobenzaprine HCI Sublingual Tablets) for PTSD

October 17, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals to Present at the Dawson James Securities 3rd Annual Small Cap Growth Conference

October 12, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals Presented at the 2nd Annual Cohen Veterans Care Summit in Washington, D.C.

September 29, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals Receives European Patent for the Active Ingredient in Tonmya® (Cyclobenzaprine HCl Sublingual Tablets)

September 14, 2017 • 4:05 PM EDT

Tonix Pharmaceuticals Elects Margaret Smith Bell to the Board of Directors

September 14, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

September 6, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals Presented Additional Phase 2 Clinical Results in Military-Related PTSD and Design of Ongoing Phase 3 Trial at the 2017 Military Health System Research Symposium

August 29, 2017 • 4:30 PM EDT

Tonix Pharmaceuticals to Present Additional Phase 2 Clinical Results and Design of Ongoing Phase 3 Trial in Military-Related PTSD at the 2017 Military Health System Research Symposium

August 21, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Programs Update

August 14, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals Announces Conditional Acceptance of Tonmya® as Proposed Brand Name for TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) for the Treatment of PTSD

July 6, 2017 • 7:00 AM EDT

Show All

News / Press Releases : Press Releases